Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica

Volumn 100, Issue 12, 2015, Pages 1571-1578

  Lipsky, Andrew H ^a,d   Farooqui, Mohammed Z H ^a   Tian, Xin ^a   Martyr, Sabrina ^a   Cullinane, Ann M ^b   Nghiem, Khanh ^b   Sun, Clare ^a   Valdez, Janet ^a   Niemann, Carsten U ^a   Herman, Sarah E M ^a   Saba, Nakhle ^a   Soto, Susan ^a   Marti, Gerald ^a   Uzel, Gulbu ^c   Holland, Steve M ^c   Lozier, Jay N ^b   Wiestner, Adrian ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRUTINIB; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLEEDING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; VERY ELDERLY; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; FOLLOW UP; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; FACTOR VIII; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PYRAZOLES; PYRIMIDINES; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 84948984640     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.126672     Document Type: Article

References (29)

1. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117(23):6287-6296.
2. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128-130.
3. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175-1184.
4. Buggy JJ, Elias L. Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy. Int Rev Immunol. 2012;31(2):119-132.
5. Byrd JC, O’Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1278-1279.
6. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
7. Sahin I, Leblebjian H, Treon SP, Ghobrial IM. Waldenstrom macroglobulinemia: from biology to treatment. Expert Rev Hematol. 2014;7(1):157-168.
8. Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120(9):1877-1887.
9. Dasmahapatra G, Patel H, Dent P, et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol. 2013; 161(1):43-56.
10. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
11. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
12. Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol. 1998; 8(20):1137-1140.
13. Oda A, Ikeda Y, Ochs HD, et al. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 crosslinking. Blood. 2000;95(5):1663-1670.
14. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood. 2006;108(8):2596-2603.
15. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015; 16(2):169-176.
16. Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28(11):2188-2196.
17. Rushworth SA, MacEwan DJ, Bowles KM. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(13):1277-1278.
18. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29(4):783-787.
19. Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand Factor-dependent platelet functions. Blood. 2014;124(26):3991-3995.
20. Pulte D, Olson KE, Broekman MJ, et al. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. J Transl Med. 2007; 5:23.
21. Coutre SE, Furman RR, Sharman JP, et al. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. ASCO Meeting Abstracts. 2014;32(15):7012.
22. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 1985;318(6045):470-472.
23. Bellucci S, Huisse MG, Boval B, et al. Defective collagen-induced platelet activation in two patients with malignant haemopathies is related to a defect in the GPVI-coupled signalling pathway. Thromb Haemost. 2005;93(1):130-138.
24. Dunkley S, Arthur JF, Evans S, et al. A familial platelet function disorder associated with abnormal signalling through the glycoprotein VI pathway. Br J Haematol. 2007;137(6):569-577.
25. Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123(21):3286-3295.
26. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost. 2005;3(8):1752-1762.
27. Li Z, Wahl MI, Eguinoa A, et al. Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases. Proc Natl Acad Sci USA. 1997;94(25):13820-13825.
28. Gilbert C, Levasseur S, Desaulniers P, et al. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor. J Immunol. 2003; 170(10):5235-5243.
29. Naresh KN, Sivasankaran P, Veliath AJ. Platelet function in chronic leukemias. Indian J Cancer. 1992;29(2):49-55